These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 4064345)
1. In-vivo metabolites of spironolactone and potassium canrenoate: determination of potential anti-androgenic activity by a mouse kidney cytosol receptor assay. Armanini D; Karbowiak I; Goi A; Mantero F; Funder JW Clin Endocrinol (Oxf); 1985 Oct; 23(4):341-7. PubMed ID: 4064345 [TBL] [Abstract][Full Text] [Related]
2. Effect of spironolactone and potassium canrenoate on cytosolic and nuclear androgen and estrogen receptors of rat liver. Francavilla A; Di Leo A; Eagon PK; Polimeno L; Guglielmi F; Fanizza G; Barone M; Starzl TE Gastroenterology; 1987 Oct; 93(4):681-6. PubMed ID: 3623016 [TBL] [Abstract][Full Text] [Related]
3. Spironolactone and potassium canrenoate in normal man. Ramsay L; Shelton J; Harrison I; Tidd M; Asbury M Clin Pharmacol Ther; 1976 Aug; 20(2):167-77. PubMed ID: 780038 [TBL] [Abstract][Full Text] [Related]
4. Canrenone and androgen receptor-active materials in plasma of cirrhotic patients during long-term K-canrenoate or spironolactone therapy. Andriulli A; Arrigoni A; Gindro T; Karbowiak I; Buzzetti G; Armanini D Digestion; 1989; 44(3):155-62. PubMed ID: 2697627 [TBL] [Abstract][Full Text] [Related]
5. Spironolactone and canrenoate-K: relative potency at steady state. Ramsay L; Asbury M; Shelton J; Harrison I Clin Pharmacol Ther; 1977 May; 21(5):602-9. PubMed ID: 858213 [TBL] [Abstract][Full Text] [Related]
6. Effects of repeated administration of potassium canrenoate (SC-14266) on serum gonadotrophin, prolactin, testosterone and progesterone in male rats. Muraki T; Nakadate T; Kubota K; Tokunaga Y; Kato R Experientia; 1980 Jun; 36(6):668-9. PubMed ID: 6774884 [TBL] [Abstract][Full Text] [Related]
7. Effects of spironolactone, canrenone and canrenoate-K on cytochrome P450, and 11beta- and 18-hydroxylation in bovine and human adrenal cortical mitochondria. Cheng SC; Suzuki K; Sadee W; Harding BW Endocrinology; 1976 Oct; 99(4):1097-106. PubMed ID: 976190 [TBL] [Abstract][Full Text] [Related]
8. Effect of spironolactone, potassium canrenoate, and their common metabolite canrenone on Dimension Vista Digoxin Assay. Dasgupta A; Johnson MJ J Clin Lab Anal; 2010; 24(6):413-7. PubMed ID: 21089173 [TBL] [Abstract][Full Text] [Related]
9. Increase in the basal tone of guinea pig thoracic aorta induced by ouabain is inhibited by spironolactone canrenone and potassium canrenoate. Sorrentino R; Cirino G; Calignano A; Mancuso F; Sorrentino L; Andriuoli G; Pinto A J Cardiovasc Pharmacol; 1996 Oct; 28(4):519-25. PubMed ID: 8891876 [TBL] [Abstract][Full Text] [Related]
10. Effect of spironolactone and its metabolites on contractile property of isolated rat aorta rings. Sorrentino R; Autore G; Cirino G; d'Emmanuele de Villa Bianca R; Calignano A; Vanasia M; Alfieri C; Sorrentino L; Pinto A J Cardiovasc Pharmacol; 2000 Aug; 36(2):230-5. PubMed ID: 10942165 [TBL] [Abstract][Full Text] [Related]
11. Bidirectional (positive/negative) interference of spironolactone, canrenone, and potassium canrenoate on serum digoxin measurement: elimination of interference by measuring free digoxin or using a chemiluminescent assay for digoxin. Dasgupta A; Saffer H; Wells A; Datta P J Clin Lab Anal; 2002; 16(4):172-7. PubMed ID: 12112389 [TBL] [Abstract][Full Text] [Related]
12. Antiandrogenic effect of spirolactones: mechanism of action. Corvol P; Michaud A; Menard J; Freifeld M; Mahoudeau J Endocrinology; 1975 Jul; 97(1):52-8. PubMed ID: 166833 [TBL] [Abstract][Full Text] [Related]
13. Topical canrenoic acid. Quantification of the antiandrogenic activity in the hamster flank organ. Noto G; Pravatá G; Bongiorno MR; Bosco M; Aricó M Int J Dermatol; 1991 Nov; 30(11):810-3. PubMed ID: 1757185 [TBL] [Abstract][Full Text] [Related]
14. [Antiandrogenic effect of spirolactones: different mechanisms of action (author's transl)]. Mahoudeau JA; Corvol P; Valcke JC; Menard J; Bricaire H Ann Endocrinol (Paris); 1976; 37(1):57-8. PubMed ID: 1015793 [TBL] [Abstract][Full Text] [Related]
15. Clinically insignificant negative interferences of spironolactone, potassium canrenoate, and their common metabolite canrenone in new dimension vista LOCI digoxin immunoassay. Dasgupta A; Johnson MJ; Sengupta TK J Clin Lab Anal; 2012 May; 26(3):143-7. PubMed ID: 22628228 [TBL] [Abstract][Full Text] [Related]
16. Antagonism of endogenous mineralocorticoids in normal subjects by prorenoate potassium and spironolactone. Levine D; Ramsay L; Auty R; Branch R; Tidd M Eur J Clin Pharmacol; 1976 Mar; 09(5-6):381-6. PubMed ID: 786663 [TBL] [Abstract][Full Text] [Related]
17. Difference in metabolic profile of potassium canrenoate and spironolactone in the rat: mutagenic metabolites unique to potassium canrenoate. Cook CS; Hauswald CL; Schoenhard GL; Piper CE; Patel A; Radzialowski FM; Hribar JD; Aksamit W; Finnegan P; Bible RH Arch Toxicol; 1988 Jan; 61(3):201-12. PubMed ID: 3355365 [TBL] [Abstract][Full Text] [Related]
18. Relative potency of prorenoate and spironolactone in normal man. Ramsay L; Harrison I; Shelton J; Tidd M Clin Pharmacol Ther; 1975 Oct; 18(4):391-400. PubMed ID: 1100306 [TBL] [Abstract][Full Text] [Related]
19. Androgen receptor in rat skeletal muscle: characterization and physiological variations. Michel G; Baulieu EE Endocrinology; 1980 Dec; 107(6):2088-98. PubMed ID: 6968675 [TBL] [Abstract][Full Text] [Related]
20. Spironolactone and potassium canrenoate metabolism. Gardiner P Lancet; 1985 Dec 21-28; 2(8469-70):1432. PubMed ID: 2867429 [No Abstract] [Full Text] [Related] [Next] [New Search]